Bromide

Bromide

SCHEMBL366432

C=C(C)C(=O)OCC[N+](C)(C)C.[Br-]

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 known ✓ P11229 7/20 0.63
CHRM3 known ✓ P20309 7/20 0.63
CHRM5 known ✓ P08912 6/20 0.63
CHRM2 known ✓ P08172 6/20 0.59
CHRM4 known ✓ P08173 6/20 0.59
ACHE known ✓ P22303 1/20 0.43
GALR3 O60755 2/20 0.63
GAA P10253 1/20 0.63
RAB9A P51151 1/20 0.63
CHRNB2 P17787 4/20 0.59
CHRNA4 P43681 4/20 0.59
CHRNA7 P36544 3/20 0.59
HTR1A P08908 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
PGR P06401 1/20 0.59
TBXA2R P21731 1/20 0.59
CHRNB4 P30926 1/20 0.59
CHRNA3 P32297 1/20 0.59
CHRNA10 Q9GZZ6 1/20 0.59
CHRNA9 Q9UGM1 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15954 0.98 CHRM5 (0.65) CHRM1CHRM3CHRM5GALR3GAA
SCHEMBL180003 0.98 CHRM5 (0.65) CHRM1CHRM3CHRM5GALR3GAA
Hydrochloric Acid SCHEMBL30183040 0.98 CHRM5 (0.65) CHRM1CHRM3CHRM5GALR3GAA
SCHEMBL29649178 0.96 CHRM5 (0.63) CHRM1CHRM3CHRM5GALR3GAA
SCHEMBL31575073 0.96 CHRM5 (0.63) CHRM1CHRM3CHRM5GALR3GAA
Iodide SCHEMBL723953 0.96 CHRM5 (0.63) CHRM1CHRM3CHRM5GALR3GAA
SCHEMBL28715059 0.96 CHRM5 (0.63) CHRM1CHRM3CHRM5GALR3GAA
Ammonia Solution, Strong SCHEMBL468696 0.96 CHRM5 (0.63) CHRM1CHRM3CHRM5GALR3GAA
Hydrochloric Acid SCHEMBL9492830 0.96 CHRM5 (0.63) CHRM1CHRM3CHRM5GALR3GAA
Hydrochloric Acid SCHEMBL28351837 0.96 CHRM5 (0.63) CHRM1CHRM3CHRM5GALR3GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122060110-A Polymerizable organic-inorganic hybrid flexible gel scintillator material and preparation method and application thereof 福州大学 2026-05-19 CN claimed
US-20260061062-A1 MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM UNIV NEBRASKA (US) 2026-03-05 US claimed
CN-119662169-B Negative electrode binder, negative electrode sheet and secondary battery 深圳好电科技有限公司 2025-06-13 CN claimed
CN-119529714-B Adhesive, negative plate and battery 深圳好电科技有限公司 2025-06-03 CN claimed
US-20250115832-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2025-04-10 US claimed
CN-119768455-A Anion exchange membrane and preparation method thereof 东丽尖端素材株式会社 2025-04-04 CN claimed
CN-119662169-A Negative electrode binder, negative electrode sheet and secondary battery 深圳好电科技有限公司 2025-03-21 CN claimed
CN-119529714-A Adhesive, negative plate and battery 深圳好电科技有限公司 2025-02-28 CN claimed
CN-117107528-B Normal temperature dyeing method and dyed product obtained by same 水木聚力接枝纺织新技术(深圳)有限公司 2025-02-25 CN claimed
CN-115400601-B Anti-pollution ion exchange membrane and preparation method and application thereof 浙江大学 2025-02-11 CN claimed
WO-2003030872-A2 COMPOSITIONS HAVING A COMBINATION OF PARTICLES FOR IMMEDIATE RELEASE AND FOR CONTROLLED RELEASE ELAN PHARMA INTERNATIONAL LTD. (IE) 2003-04-17 WO claimed
WO-2003024425-A1 NANOPARTICULATE INSULIN FORMULATIONS ELAN PHARMA INTERNATIONAL, LTD. (IE) 2003-03-27 WO claimed
US-20030045637-A1 Pigment dispersing resin KANSAI PAINT CO., LTD. (JP) 2003-03-06 US claimed
EP-1270624-A1 RESIN FOR PIGMENT DISPERSION KANSAI PAINT CO., LTD. (JP) 2003-01-02 EP claimed
WO-2002088318-A2 LIPID-COMPRISING DRUG DELIVERY COMPLEXES AND METHODS FOR THEIR PRODUCTION TARGETED GENETICS CORPORATION (US) 2002-11-07 WO claimed
EP-1247821-A2 Pigment dispersing resin KANSAI PAINT CO., LTD. (JP) 2002-10-09 EP claimed
US-6001549-A IMAGING ELEMENT CONTAINING ANTISTATIC AGENT EASTMAN KODAK COMPANY (US) 1999-12-14 US claimed
US-5618622-A ANIONIC CARBOXYLIC ACID OR SULFONIC ACID GROUP-CONTAINING HYDROCARBON POLYMER WITH CHITOSAN POLYELECTROLYTE COATING KIMBERLY-CLARK CORPORATION (US) 1997-04-08 US claimed
WO-1997002077-A2 SURFACE-MODIFIED FIBROUS MATERIAL AS A FILTRATION MEDIUM KIMBERLY-CLARK WORLDWIDE, INC. (US) 1997-01-23 WO claimed
US-4445521-A ANIONIC AND CATIONIC POLYMER COMBINATION L'OREAL (FR) 1984-05-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260061062-A1 MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM CD44, ALG1, HSF1 CHRM1 85/4885CHRM3 167/4885CHRM5 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.